Eli Lilly warms up for summer launch with long-term success goal
US-based Eli Lilly is expecting to launch type 2 diabetes treatment tirzepatide this summer without intending to disrupt the market. According to the company, it’s all about ensuring success on the long term, which could be good news for competitor Novo Nordisk.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY DANIEL PEDERSEN
Eli Lilly is making explicit comments to the market that could be positively interpreted for competitor Novo Nordisk.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk could lose millions on discount dispute in US
For subscribers
Eli Lilly's Trulicity beats growth expectations
For subscribers
